tradingkey.logo
tradingkey.logo
Buscar

Maravai LifeSciences Holdings Inc

MRVI
Añadir a la lista de seguimiento
4.340USD
-0.030-0.69%
Horarios del mercado ETCotizaciones retrasadas 15 min
640.13MCap. mercado
PérdidaP/E TTM

Maravai LifeSciences Holdings Inc

4.340
-0.030-0.69%

Más Datos de Maravai LifeSciences Holdings Inc Compañía

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.

Información de Maravai LifeSciences Holdings Inc

Símbolo de cotizaciónMRVI
Nombre de la empresaMaravai LifeSciences Holdings Inc
Fecha de salida a bolsaNov 20, 2020
Director ejecutivoBrust (Bernd)
Número de empleados570
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 20
Dirección10770 Wateridge Circle Suite 200
CiudadSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92121
Teléfono18585460004
Sitio Webhttps://www.maravai.com/
Símbolo de cotizaciónMRVI
Fecha de salida a bolsaNov 20, 2020
Director ejecutivoBrust (Bernd)

Ejecutivos de Maravai LifeSciences Holdings Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
429.95K
+27.80%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+63.27%
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
316.63K
-28.85%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
264.91K
+33.65%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
169.91K
--
Mr. Luke Joseph Marker
Mr. Luke Joseph Marker
Director
Director
138.06K
--
Mr. Constantine S. (Dean) Mihas
Mr. Constantine S. (Dean) Mihas
Director
Director
--
--
Mr. Sean L. Cunningham
Mr. Sean L. Cunningham
Director
Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
429.95K
+27.80%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+63.27%
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
316.63K
-28.85%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
264.91K
+33.65%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2025
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
North America
112.38M
60.50%
Asia Pacific
41.47M
22.33%
Europe, the Middle East and Africa
30.92M
16.65%
Latin and Central America
971.00K
0.52%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: hace 18 horas
Actualizado: hace 18 horas
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
GTCR Golder Rauner, LLC
13.66%
12 West Capital Management, L.P.
6.05%
Braidwell LP
5.66%
Hudson View Capital LLC
5.41%
BlackRock Institutional Trust Company, N.A.
5.38%
Otro
63.84%
Accionistas
Accionistas
Proporción
GTCR Golder Rauner, LLC
13.66%
12 West Capital Management, L.P.
6.05%
Braidwell LP
5.66%
Hudson View Capital LLC
5.41%
BlackRock Institutional Trust Company, N.A.
5.38%
Otro
63.84%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
29.84%
Hedge Fund
24.12%
Investment Advisor/Hedge Fund
17.84%
Private Equity
13.66%
Individual Investor
6.46%
Corporation
5.41%
Research Firm
4.69%
Pension Fund
0.20%
Bank and Trust
0.12%

Participación institucional

Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
476
140.69M
95.39%
-29.12M
2025Q4
498
130.99M
90.33%
-38.49M
2025Q3
518
128.65M
88.93%
-44.43M
2025Q2
560
144.27M
100.21%
-25.80M
2025Q1
589
133.65M
92.84%
-44.45M
2024Q4
580
144.56M
101.93%
-33.57M
2024Q3
603
148.21M
104.79%
-33.05M
2024Q2
611
152.09M
114.44%
-19.50M
2024Q1
609
139.87M
105.40%
-26.88M
2023Q4
621
137.21M
103.78%
-26.31M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
GTCR Golder Rauner, LLC
20.15M
13.77%
--
--
Dec 31, 2025
12 West Capital Management, L.P.
8.92M
6.09%
-3.60M
-28.75%
Dec 31, 2025
Braidwell LP
8.35M
5.71%
--
--
Dec 31, 2025
Hudson View Capital LLC
7.98M
5.45%
-961.72K
-10.76%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
7.94M
5.42%
+248.40K
+3.23%
Dec 31, 2025
T. Rowe Price Investment Management, Inc.
6.34M
4.33%
+178.44K
+2.90%
Dec 31, 2025
Mackenzie Financial Corporation
6.17M
4.22%
+104.36K
+1.72%
Dec 31, 2025
Renaissance Technologies LLC
4.23M
2.89%
-93.00K
-2.15%
Dec 31, 2025
Tejara Capital Ltd.
3.02M
2.06%
+566.77K
+23.10%
Dec 31, 2025
Ver más

ETFs relacionados

Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
Global X Genomics & Biotechnology ETF
0.41%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
Ver más
Global X Genomics & Biotechnology ETF
Proporción0.41%
Invesco Nasdaq Biotechnology ETF
Proporción0.05%
ProShares Ultra Nasdaq Biotechnology
Proporción0.04%
iShares Biotechnology ETF
Proporción0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.03%
iShares Russell 2000 Value ETF
Proporción0.02%
Schwab U.S. Small-Cap ETF
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
KeyAI